Marianne Waldstrøm

Summary

Affiliation: Odense University Hospital
Country: Denmark

Publications

  1. pmc Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab
    Christine Vestergaard Madsen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    J Ovarian Res 5:23. 2012
  2. doi request reprint Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion
    Marianne Waldstrøm
    Department of Clinical Pathology, Vejle Hospital, Vejle, Denmark
    Cancer Cytopathol 121:136-45. 2013
  3. doi request reprint Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of atypical squamous cells of undetermined significance (ASC-US)
    M Waldstrom
    Department of Pathology, Vejle Hospital, Kabbeltoft, Vejle, Denmark
    Cytopathology 23:389-95. 2012
  4. pmc Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Kabbeltoft 25, DK 7100 Vejle, Denmark
    BMC Cancer 10:185. 2010
  5. doi request reprint Clinical performance of a human papillomavirus messenger RNA test (Aptima HPV Assay) on residual material from archived 3-year-old PreservCyt samples with low-grade squamous intraepithelial lesion
    Marianne Waldstrøm
    Department of Pathology and Microbiology, Vejle Hospital, Vejle, Denmark
    Arch Pathol Lab Med 135:1052-6. 2011
  6. doi request reprint Identification of BRCA1-deficient ovarian cancers
    Anne Bine Skytte
    Clinical Genetics Pathology, Vejle Hospital, Vejle, Denmark
    Acta Obstet Gynecol Scand 90:593-9. 2011
  7. doi request reprint The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 19:820-5. 2009
  8. doi request reprint Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer
    Maja Patricia Smerdel
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 19:578-84. 2009
  9. ncbi request reprint Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, DK 7100 Vejle, Denmark
    Int J Oncol 33:195-204. 2008
  10. doi request reprint Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Clin Cancer Res 14:3278-82. 2008

Collaborators

  • Karina Dahl Steffensen
  • Anders Jakobsen
  • Emma R Woodward
  • Christine Vestergaard Madsen
  • M Waldstrom
  • Anne Bine Skytte
  • Ivan Brandslund
  • Maja Patricia Smerdel
  • D Ornskov
  • Dorte Aalund Olsen
  • Maja Smerdel
  • Parvin Adimi
  • Dorthe Cruger
  • Steen Kølvraa
  • Anders Aamann Rasmussen
  • Rikke Fredslund Andersen

Detail Information

Publications10

  1. pmc Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab
    Christine Vestergaard Madsen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    J Ovarian Res 5:23. 2012
    ..abstract:..
  2. doi request reprint Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion
    Marianne Waldstrøm
    Department of Clinical Pathology, Vejle Hospital, Vejle, Denmark
    Cancer Cytopathol 121:136-45. 2013
    ..The authors also assessed the reproducibility of the evaluation of immunocytochemical staining...
  3. doi request reprint Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of atypical squamous cells of undetermined significance (ASC-US)
    M Waldstrom
    Department of Pathology, Vejle Hospital, Kabbeltoft, Vejle, Denmark
    Cytopathology 23:389-95. 2012
    ..We evaluated the clinical performance of two HPV tests: the Linear Array HPV genotyping test (LA) detecting HPV DNA from 37 oncogenic and non-oncogenic HPV types and the Aptima HPV assay detecting E6/E7 mRNA from 14 oncogenic HPV types...
  4. pmc Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Kabbeltoft 25, DK 7100 Vejle, Denmark
    BMC Cancer 10:185. 2010
    ....
  5. doi request reprint Clinical performance of a human papillomavirus messenger RNA test (Aptima HPV Assay) on residual material from archived 3-year-old PreservCyt samples with low-grade squamous intraepithelial lesion
    Marianne Waldstrøm
    Department of Pathology and Microbiology, Vejle Hospital, Vejle, Denmark
    Arch Pathol Lab Med 135:1052-6. 2011
    ..However, mRNA is less stable than DNA, thus posing a challenge to the preservation abilities of the cell-collecting medium...
  6. doi request reprint Identification of BRCA1-deficient ovarian cancers
    Anne Bine Skytte
    Clinical Genetics Pathology, Vejle Hospital, Vejle, Denmark
    Acta Obstet Gynecol Scand 90:593-9. 2011
    ..As DNA sequencing is expensive and time consuming, efforts have been devoted to develop more indirect methods for BRCA screening that can improve the selection of patients for sequence-based BRCA testing...
  7. doi request reprint The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 19:820-5. 2009
    ....
  8. doi request reprint Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer
    Maja Patricia Smerdel
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Int J Gynecol Cancer 19:578-84. 2009
    ..The aim of the present study was to examine the possible importance of 2 VEGF polymorphisms and VEGF-A expression in ovarian cancer...
  9. ncbi request reprint Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, DK 7100 Vejle, Denmark
    Int J Oncol 33:195-204. 2008
    ....
  10. doi request reprint Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors
    Karina Dahl Steffensen
    Department of Oncology, Vejle Hospital, Vejle, Denmark
    Clin Cancer Res 14:3278-82. 2008
    ..EGFRvIII has not been found in normal tissue, and consequently, it is an attractive tumor-specific candidate for molecular targeted treatment. The literature dealing with this mutation in ovarian cancer has been very sparse...